Report error Found 138 Enz. Inhib. hit(s) with all data for entry = 13040
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 2nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 3nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12V]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase (Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 3nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 4nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase (Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 7nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 10nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12V]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase (Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 10nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 15nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 17nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 18nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 19nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 20nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 22nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 23nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 27nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 32nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 34nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 38nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 38nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 39nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 40nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 44nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 45nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 46nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 47nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 47nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 53nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 56nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 56nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 64nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 71nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 73nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 74nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 79nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12D]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase (Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 85nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 88nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 89nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 98nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 100nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 104nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 108nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 115nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 122nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 124nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 129nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12V]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase (Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 136nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 148nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 176nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase(Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 199nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair
TargetGTPase KRas [G12V]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase (Human)
Hoffmann-La Roche
US Patent
Hoffmann-La Roche
US Patent
Affinity DataIC50: 217nMAssay Description:In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was...More data for this Ligand-Target Pair











































